What recent performance tells you about Supernus Pharmaceuticals

Supernus Pharmaceuticals (SUPN) has drawn investor attention after recent trading, with the stock around $49.91 and a mixed pattern of returns that includes a 1 day decline and a 7 day pullback.

Over the past month the share price shows a small decline, while the past 3 months reflect a gain. Looking further back, total returns over 1 year, 3 years, and 5 years are all positive on the figures provided.

The recent 1 day and 7 day share price declines sit against a positive 90 day share price return of 5.56% and a 1 year total shareholder return of 59.66%. This suggests earlier momentum has eased in the very short term, while longer term holders have still seen strong gains.

If this mixed picture in a specialist CNS drug maker has your attention, it could be a good moment to broaden your search with our list of 33 healthcare AI stocks.

With Supernus trading around $49.91, a value score of 5, and various targets suggesting room above the current price, the key question for investors is whether this reflects a genuine mispricing or whether the market is already factoring in future growth.

Most Popular Narrative: 21% Undervalued

With Supernus Pharmaceuticals last closing at $49.91 against a narrative fair value estimate of $63.17, the most followed view sees meaningful upside potential based on detailed cash flow and earnings work.

Expanding patient pool for core products, Qelbree and GOCOVRI, driven by increased prevalence and diagnosis of CNS disorders, as well as broader healthcare access (especially among Medicare patients, as seen with GOCOVRI’s prescription growth), is likely to sustain robust top-line revenue growth.

Commercial infrastructure and recent launch of ONAPGO position Supernus to capture further market share in Parkinson’s disease, benefiting from demographic aging and rising CNS disease burden, which should materially boost revenue and improve gross margins as fixed costs are leveraged.

Wondering how this CNS focused story gets to that valuation gap? The narrative leans on steady revenue expansion, shifting margins, and a richer earnings multiple. Curious which assumptions really move the fair value line and how long the market is expected to wait for them to play out?

Result: Fair Value of $63.17 (UNDERVALUED)

However, there are still real pressure points, including heavy reliance on a few key drugs and rising SG&A and R&D costs that keep GAAP operating losses in focus.

Next Steps

Given this mix of optimism and concern, do you want to see what stands out most right now and form your own view quickly? Our breakdown highlights 3 key rewards and 1 important warning sign so you can weigh both sides before you act.

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock. The right mix of ideas can be the difference between reacting and being prepared.

• Target resilience with 68 resilient stocks with low risk scores to help you focus on companies with steadier profiles when markets feel choppy.
• Hunt for value with 48 high quality undervalued stocks that highlight companies where fundamentals and price appear out of sync.
• Build a list of potential income anchors through 14 dividend fortresses that focus on higher yielding dividend payers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.